Determination of clopidogrel by chromatography

Current Pharmaceutical Analysis

Volumn 5, Issue 4, 2009, Pages 424-431

  Vocilkova, Lenka ^a,b   Opatrilova, Radka ^c   Sramek, Vladimir ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Clopidogrel; HPLC; Tablets

Indexed keywords

CLOPIDOGREL; DRUG METABOLITE; PREGREL; UNCLASSIFIED DRUG;

CHROMATOGRAPHY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG PURITY; FILM COATING; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; TABLET; THIN LAYER CHROMATOGRAPHY;

RATTUS NORVEGICUS;

EID: 75149169390     PISSN: 15734129     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341209789649131     Document Type: Review

References (50)

1. Mills, D.C.; Puri, R.; Hu, C.J.; Minniti, C.; Grana, G.; Freedman, M.D.; Colman, R.F.; Colman, R.W. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosc. Thromb., 1992, 12, 430-436.
2. Majerus, P.W.; Tollefsen, D.M. Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs, In: Brunton, L.L., Ed., The Pharmacological Basis of Therapeutics, 11th edition, The McGraw-Hill Companies, New York, 2006, p. 1483.
3. www.RXlist.com, PLAVIXTM, RxMed: Pharmaceutical Information, Sanofi/Bristol- Mayers Squibb
4. http://www.fda.gov/medwatch/safety/2007/May-PI/Plavix-PI.pdf
5. Savi, P.; Combalbert, J.; Gaich, C.; Rouchon, M.C.; Maffrand, J.P.; Berger, Y.; Herbert, J.M. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb. Haemost., 1994, 72, 313-317.
6. Pereillo, J.M.; Maftouh, M.; Andrieu, A.; Uzabiaga, M.F.; Fedeli, O.; Savi, P.; Pascal, M.; Herbert, J.M.; Maffrand, J.P.; Picard, C. Structure and Stereochemistry of the Active Metabolite of Clopidogrel. Drug Metabol. Dispos., 2002, 30(11), 1288-1295.
7. Gomez, Y.; Adams, E.; Hoogmartens, J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J. Pharm. Biomed. Anal., 2004, 34, 341-348.
8. Ki, M.H.; Choi, M.H.; Ahn, K.B.; Kim, B.S.; Im, D.S.; Ahn, S.K.; Shin, H.J. The Efficacy and Safety of Clopidogrel Resinate as A Novel Polymeric Salt Form of Clopidogrel. Arch. Pharm. Res., 2008, 31(2), 250-258.
9. Herbert, J.M.; Frehel, D.; Vallee, E.; Kieffer, G.; Gouy, D.; Berger, Y.; Defreyn, G.; Maffrand, J.P. Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent. Cardiovasc. Drug, 1993, 11(2), 180-198.
10. Rao, T.R.; Usha, P.R.; Naidu, M.U.; Gogtay, J.A.; Meena, M. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr. Therap. Res., 2003, 64(9), 685-696.
11. Ksycinska, H.; Rudzki, P.; Bukowska-Kiliszek, M. Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. J. Pharm. Biomed. Anal., 2006, 41(2), 533-539.
12. Kam, P.C.A.; Nethery, C.M. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia, 2008, 58(1), 28-35.
13. McEwen, J.; Strauch, G.; Perles, P.; Fowter, G.; Moreland, T.; Dickinson, J.P.; Meontels, R.; Mosser, J.; Neccian, J. Clopidogrel bioavailability is unaffected by food or antacids. J. Clin. Pharmacol., 1996, 36(9), 856.
14. Vilahur, G.; Choi, B.G.; Zafar, M.U.; Viles-Gonzalez, J.F.; Vorchheimer, D.A.; Fuster, V.; Badimon, J.J. Normalization of platelet reactivity in clopidogrel-treated subjects. J. Tromb. Haemost., 2007, 5(1), 82-90.
15. Hongo, R.H.; Ley, J.; Dick, S.E.; Yee, R.R. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J. Am. Coll. Cardiol., 2002, 40(2), 231-237.
16. Kim, K.A.; Park, P.W.; Park, J.Y. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eu. J. Clin. Pharmacol., 2008, 64(6), 589-597.
17. Nirogi, R.V.S.; Kandikere, V.N.; Shukla, M.; Mudigonda, K.; Maurya, S.; Boosi, R. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Mass Spectrom., 2006, 20(11), 1695-1700.
18. Kulkarni, R.A. Clopidogrel in cardiovascular disorders. J. Postgrad. Med., 2000, 46(4), 312-313.
19. Escolar, G.; Heras, M. Clopidogrel: A selective inhibitor of platelet ADP receptors. Drugs Today, 2000, 36(4), 187.
20. Weber, A.A.; Reimann, S.; Schrör, K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br. J. Pharmacol., 1999, 126(2), 415-420.
21. Schrör. K. The Basic Pharmacology of Ticlopidine and Clopidogrel. Platelets, 1993, 4(5), 252-261.
22. Fuchs, I.; Frossard, M.; Laggner, A.; Spiel, V; Wohlschläger, E.; Jilma B. Pharmacodynamics (PD) of clopidogrel in patients with acute coronary syndromes undergoing percutaneous interventions (PCI). Clin. Pharmacol. Therap., 2005, 77(2), P53.
23. Li, J.S.; Yow, E.; Berezny, K.Y.; Bokesch, P.M.; Takahashi, M.; Graham, T.P.; Sanders, S.P.; Sidi, D.; Bonnet, D.; Ewert, P.; Jennings, L.K; Michelson, D. Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children. Circulation, 2008, 117(4), 553-559.
24. Deray, G.; Bagnis, C.; Brouard, R.; Necciari, J.; Leenhardt, A.F.; Raymond, F.; Baumelou, A. Clopidogrel Activities in Patients with Renal Function Impairment. Clin. Drug Investig., 1998, 16(4), 319-328.
25. Gurbel, P.A.; O'Connor, C.M.; Cummings, C.C.; Serebruany, V.L. Clopidogrel: the future choice for preventing platelet activation during coronary stenting? Pharmacol. Res., 1999, 40(2), 107-111.
26. CAPRIE Steering Committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet, 1996, 348(9038), 1329-1339.
27. The CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N. Engl. J. Med., 2001, 345(7), 494-502.
28. Easton, J.D. Clinical aspects of the use of Clopidogrel, a new antiplatelet agent. Semin. Tromb. Haemost., 1999, 25(Suppl 2), 69-75.
29. Bertrand, M.E.; Rupprecht, H.J.; Urban, P.; Gershlick, A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation, 2000, 102(6), 624-629.
30. Bhatt, D. L.; Topol, J.E. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Am. Heart J., 2004, 148(2), 263-268.
31. Gurbel, P.A.; Cummings, C.C.; Bell, C.R.; Alford, A.B.; Meister, A.F.; Serebruany, V.L. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the plavix reduction of new thrombus occurrence (PRONTO) trial. Am. Heart J., 2003, 145(2), 239-247.
32. Steinhubl, S.R.; Berger, P.B.; Mann, J.T.; Fry, E.T.; DeLago, A.; Wilmer, C.; Topol, E.J.; CREDO Investigators. Early and susteined dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA, 2002, 288(19), 2411-2420.
33. Nirogi, R.V.S.; Kandikere, V.N.; Shukla, M.; Mudigonda, K.; Maurya, S.; Boosi, R. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom., 2006, 20(11), 1695-1700.
34. Robinson, A.; Hillis, J.; Neal, C.; Leary, A.C. The validation of a bioanalytical method for the determination of clopidogrel in human plasma. J. Chromatogr. B, 2007, 848(2), 344-354.
35. Agrawal, H.; Kaul, N.; Paradkar, A.R. ; Mahadik, K.R. Stability indicating HPTLC determination of clopidogrel bisulphate as bulk drug and in pharmaceutical dosage form. Talanta, 2003, 61(5), 581-589.
36. Patel, R.B.; Shankar, M.B.; Patel, M.R.; Bhatt, K.K. Simultaneous estimation of acetylsalicylic acid and clopidogrel bisulfate in pure powder and tablet formulations by high-performance column liquid chromatography and high-performance thin-layer chromatography. J. AOAC Int., 2008, 91(4), 750-755.
37. Antić, D.; Filipić, S.; Araba, D. A simple and sensitive TLC method for determination of clopidogrel and its impurity SR 26334 in pharmaceutical products, Acta Chromatographica, 2007, 18, 199-206.
38. Mitakos, A.; Panderi, I. A validated LC method for the determination of clopidogrel in pharmaceutical preparations. J. Pharm. Biomed. Anal., 2002, 28(3-4), 431-438.
39. Lainesse, A.; Ozalp, Y.; Wong, H.; Alpan, R,S. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung, 2004, 54(9A), 600-604.
40. Sippel, J.; Sfair, L.L.; Schapoval, E.E.; Steppe, M. New high-performance liquid chromatographic method for determination of clopidogrel in coated tablets. J AOAC Int., 2008, 91(1), 67-72.
41. Mohan, A.; Hariharan, M.; Vikraman, E.; Subbaiah, G.; Venkataraman, B.R.; Saravanan, D. Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product. J. Pharm. Biomed. Anal., 2008, 47(1), 183-189
42. Bahrami, G.; Mohammadi, B.; Sisakhtnezhad, S. High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 864(1-2), 168-172.
43. Souri, E.; Jalalizadeh, H.; Kebriaee-Zadeh, A.; Shekarchi, M.; Dalvandi, A. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed. Chromatogr., 2006, 20(12), 1309-1314.
44. Mitakos, A.; Panderi, I. Determination of the carboxylic acid metabolite of clopidogrel in human plasma by liquid chromatography-electrospray ionization mass spectrometry. Anal. Chim. Acta, 2004, 505(1), 107-114.
45. Mani, H.; Toennes, S.W.; Linnemann, B.; Urbanek, D.A.; Schwonberg, J.; Kauert, G.F.; Lindhoff-Last, E. Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy? Ther. Drug. Monit., 2008, 30(1), 84-89.
46. Patel, N.K.; Subbaiah, G.; Shah, H.; Kundlik, M.; Shrivastav, P.S. Rapid LC-ESI-MS-MS method for the simultaneous determination of clopidogrel and its carboxylic acid metabolite in human plasma. J. Chromatogr. Sci., 2008, 46(10), 867-875.
47. Takahashi, M.; Pang, H.; Kawabata, K.; Farid, N.A.; Kurihara, A. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LC/MS/MS J. Pharm. Biomed. Anal., 2008, 48(4), 1219-1224.
48. Lagorce, P.; Perez, Y.; Ortiz, J.; Necciari, J.; Bressollec, F. Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry. J. Chromatogr. B, 1998, 720(1-2), 107-117.
49. Singh, S.S.; Sharma, K.; Barot, D.; Mohan, P.R.; Lohray, V.B. Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. J. Chromatogr. B, 2005, 821(2), 173-18.
50. Wada, M.; Nishiwaki, J.; Yamane, T.; Ohwaki, Y.; Aboul-Enein, H.Y.; Nakashima, K. Interaction study of aspirin or clopidogrel on pharmacokinetics of donepezil hydrochloride in rats by HPLC-fluorescence detection. Biomed. Chromatogr., 2007, 21(6), 616-620.